Hippocratic AI Achieves HITRUST e1 Certification for Full Agentic Platform
What HITRUST e1 Certification Means
Achieving HITRUST certification is widely regarded as a gold standard for healthcare cybersecurity, demonstrating an organization's commitment to safeguarding protected health information (PHI). The HITRUST e1 Certification, known as the 'HITRUST Essentials, 1-Year' assessment, encompasses the 44 most critical security controls and provides a one-year validated certification. Achieving the certification means Hippocratic AI has implemented foundational cybersecurity practices and had them independently validated, offering assurance that robust data protection measures are in place. For a company like Hippocratic AI, which deploys AI solutions in highly regulated healthcare settings, this milestone signals to clients and partners that its platform meets rigorous industry-defined security and compliance standards.
Hippocratic AI has ingrained a culture of safety from day one. Every team member takes a 'Do No Harm' oath upon joining, pledging to prioritize the safety of the company's products above all else. This philosophy is reflected in how the platform is built and operated, embedding strong safeguards for patient privacy and data security at every level.
'Security and patient safety have always been top priorities for Hippocratic AI, and attaining HITRUST certification validates that commitment,' said Matt Honea, Chief Information Security Officer at Hippocratic AI. 'As we empower healthcare organizations with our AI platform, this certification assures them that we uphold the highest industry standards for protecting sensitive data and maintaining their trust.'
'The HITRUST e1 Validated Assessment is a good tool for cyber-aware organizations like Hippocratic AI that want to build assurances and progressively demonstrate due diligence around information security and privacy,' said Robert Booker, Chief Strategy Officer at HITRUST. 'We applaud Hippocratic AI for their commitment to cybersecurity and successful completion of their HITRUST e1 Certification.'
The HITRUST certification comes as Hippocratic AI continues to innovate with a safety-first approach to generative AI in healthcare. The company provides specialized generative AI agents that perform non-diagnostic, patient-facing outreach, allowing healthcare teams to extend care with greater efficiency and empathy. Hippocratic AI's proprietary Polaris constellation architecture has demonstrated high clinical accuracy and has powered over 2.5 million patient calls, while achieving a high patient satisfaction rate of 8.95/10. By coupling such advanced capabilities with rigorous security controls and oversight, Hippocratic AI ensures that healthcare institutions can confidently integrate its AI solutions into sensitive clinical workflows without compromising on safety, patient experience or privacy. This newly earned HITRUST certification serves as a validation of that approach and a foundation for the company's ongoing efforts to maintain the highest levels of trust and reliability in healthcare AI deployment.
About Hippocratic AI
Hippocratic AI has developed a safety-focused Large Language Model (LLM) for healthcare. The company believes that a safe LLM can dramatically improve healthcare accessibility and health outcomes in the world by bringing deep healthcare expertise to every human. No other technology has the potential to have this level of global impact on health. The company was co-founded by CEO Munjal Shah, alongside a group of physicians, hospital administrators, healthcare professionals, and artificial intelligence researchers from El Camino Health, Johns Hopkins, Stanford, Microsoft, Google, and NVIDIA. Hippocratic AI has received a total of $278 million in funding and is backed by leading investors, including Andreessen Horowitz, General Catalyst, Kleiner Perkins, NVIDIA's NVentures, Premji Invest, SV Angel, and six health systems. For more information on Hippocratic AI, visit www.hippocraticai.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
13 minutes ago
- Business Wire
Take 2 R&S LLC Positioned as Industry Leader as California Mandates Safety Advisors in Film & TV Tax Credit Program
LOS ANGELES--(BUSINESS WIRE)--With the California Film Commission's recent enhancement to its Film & Television Tax Credit Program, mandating Safety Advisors on qualifying productions, Take 2 R&S LLC is proud to announce its readiness to meet this critical industry need with unparalleled expertise, infrastructure, and talent. Effective immediately, all productions receiving the California Tax Incentive must now retain Safety Advisors to oversee compliance with set safety protocols. This move—designed to elevate health and safety standards—mirrors longstanding studio-level expectations and aims to protect cast and crew across all production environments. Take 2 R&S LLC, a trusted partner in risk and safety management, is the only firm in California uniquely positioned to fulfill this mandate at scale. The company offers a turnkey solution modeled after major studio safety departments, combining decades of hands-on experience with a robust roster of certified professionals. 'This new requirement aligns perfectly with what we've been doing for years,' said Michael Tamburro, Founder of Take 2 R&S LLC. 'Our team doesn't just check boxes—we integrate safety into the culture of each production. We've built a structure that mirrors the major studios and can scale immediately to support both indie and large-scale projects.' Take 2's Safety Advisors are more than compliance officers—they are production veterans with specialized training in film and television safety standards, OSHA protocols, and incident prevention. The company supports clients with: On-set Safety Advisors tailored to each project's scale and complexity Studio-style infrastructure including incident reporting systems, site inspections, and daily safety briefings Close collaboration with producers, line staff, and labor unions to meet and exceed state mandates As Hollywood adapts to this evolving regulatory landscape, Take 2 R&S LLC is already delivering proactive, trusted solutions—ensuring productions remain eligible for tax incentives while protecting the people who bring stories to life.
Business Wire
2 hours ago
- Business Wire
Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website
BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a comprehensive upgrade to its preclinical business division. The upgrade features an expanded portfolio of genetically engineered animal models—including target-humanized, immune-humanized, transgenic, and immunodeficient mice—alongside a full suite of preclinical services such as efficacy studies, PK/PD analysis, biomarker evaluation, and non-GLP toxicology testing. In parallel, the company also launched its new official website ( featuring an intuitive structure, enriched content, and an optimized multilingual user experience to serve global clients and partners better. Extensive Model Portfolio with Over 1,100 Target-Humanized Mouse Models In 2021, Biocytogen launched the 'BioMice' sub-brand to advance its portfolio of genetically engineered mouse models. Leveraging its proprietary gene-editing platform, the company has developed more than 1,100 target-humanized mice. These models are generated using precise in situ gene replacement technology, which substitutes mouse genes with human sequences while preserving endogenous gene regulation. This approach enables a more accurate simulation of human physiological and pathological conditions, establishing BioMice as the gold-standard platform for evaluating the efficacy and safety of various therapeutic modalities, including antibody drugs, cell therapies, bispecific/multispecific antibodies, ADCs, and oligonucleotide-based treatments. The company has established high-value disease models for oncology, autoimmune, metabolic, and neurological disorders, including CD3 (TCEs), HER2 (TAAs), TL1A (IBD), TSLP (AD), GLP1R (muscle gain/weight loss), and TFR1 (BBB delivery). These models are widely used for target validation, mechanistic studies, and preclinical evaluations. To date, safety data generated from these models have supported 15 IND approvals by China's NMPA and 5 IND approvals by the U.S. FDA (including 4 dual submissions). Biocytogen also offers immune-humanized mouse models (e.g., huPBMC-B-NDG, huHSC-B-NDG, huHSC-B-NDG hIL15, and huPBMC-B-NDG MHC I/II DKO plus), transgenic mice, and immunodeficient strains to support evaluations of immuno-oncology agents, T/NK cell therapies, and immunostimulatory drugs, building a comprehensive and multi-dimensional model portfolio. Global Animal Supply Network Supporting Efficient Preclinical Research Biocytogen operates three AAALAC-accredited animal facilities in Haimen (Jiangsu), Daxing (Beijing), and Boston (USA), covering a total area of 55,000 m² and offering an annual supply capacity of over 800,000 laboratory animals. With a robust quality control system and standardized microbial monitoring, Biocytogen has established an international distribution network spanning Asia, Europe, and North America. The company's mouse models have been successfully delivered to clients in over 20 countries and regions, providing reliable model support for global drug development efforts. Integrated Preclinical Services to Accelerate IND Filing and Clinical Translation Leveraging its proprietary animal models, Biocytogen provides one-stop, non-GLP preclinical products and services, including in vivo efficacy testing, PK/PD analysis, biomarker assessment, and early toxicology studies. With a vast collection of CDX and PDX tumor models and customizable study designs, Biocytogen serves over 20 therapeutic areas—including solid tumors, hematologic malignancies, autoimmune diseases, metabolic disorders, and neurodegenerative diseases—and supports a variety of drug modalities such as antibodies, small molecules, ADCs, bispecifics, cell therapies, nucleic acids, and vaccines. As of now, Biocytogen has completed more than 5,300 drug evaluation studies for nearly 900 pharmaceutical and academic institutions worldwide. Over One Million Fully Human Antibodies Empowering Antibody Drug Discovery Beyond preclinical services, Biocytogen also leads in antibody discovery through its proprietary RenMice ® platforms—including RenMab™ (fully human antibody), RenLite ® (common light chain), RenNano ® (VHH antibody), RenTCR™ (fully human TCR), and RenTCR-mimic™ (fully human TCR-mimic antibody). The company has built a library of over one million fully human antibody sequences against more than 1,000 potential therapeutic targets, with diverse structures and functional profiles. As of December 31, 2024, Biocytogen has signed approximately 200 drug co-development, licensing, or transfer agreements, including over 50 target-based RenMice ® platform collaborations with multinational pharmaceutical companies. Multiple clinical-stage antibody candidates have also been successfully out-licensed to global partners. Biocytogen's integrated capabilities in antibody discovery, screening, and engineering are accelerating the transition from target validation to clinical candidate selection, empowering global biopharmaceutical innovation. New Official Website Launched to Serve Global Clients To enhance global service capabilities, Biocytogen has officially launched its new website: Designed for a clean and intuitive user experience, the new site features streamlined architecture, upgraded content organization, improved search functionality, and multilingual support in Chinese, English, Japanese, and Korean. Structured around its two main business divisions—BioMice ® for preclinical products and services and RenBiologics™ for antibody discovery and collaboration—the site offers a comprehensive overview of Biocytogen's model products, antibody assets, project portfolios, and service capabilities. It provides an efficient and direct information portal for global partners and supports the company's ongoing internationalization strategy. About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice ® (RenMab™/ RenLite ® / RenNano ® / RenTCR-mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice ® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit
Business Wire
3 hours ago
- Business Wire
The Open Group Launches The Open Group Open Digital Transformation™ Forum
SAN FRANCISCO--(BUSINESS WIRE)--The Open Group, the vendor-neutral technology consortium, has today announced the formation of The Open Group Open Digital Transformation™ Forum (ODXF). This new initiative will support enterprise Digital Transformation by developing and popularizing pragmatic, open standards in this increasingly valuable and challenging space. By establishing clear guidelines for Digital Transformation initiatives and enabling cross-industry collaboration to share insights and best practices, ODXF aims to ensure that a greater share of Digital Transformation investment globally delivers effective returns on investment and measurably positive impacts on cultural, workforce, and technological changes. 'The vast majority of enterprises today are engaged in Digital Transformation initiatives, with significant global spend in Digital Transformation,' commented Rashed Al-Yami, Governing Board Member of The Open Group and Manager Digital Platforms & Architecture Design Division at Aramco. 'By developing open standards through vendor-neutral collaboration, ODXF can influence the Digital Transformation agenda towards more rigorous and successful practices.' Key focus areas for ODXF include developing standardized frameworks for Digital Transformation initiatives, ensuring consistency, and producing reference architectures which organizations can incorporate in order to make their own Digital Transformation journeys more agile and responsive. The Forum will also collaborate on establishing a body of knowledge, which incorporates a range of documents designed to help users operationalize the standard, as well as ultimately delivering a certification program for practitioners to demonstrate that they understand and can apply best-in-class approaches to Digital Transformation. 'Digital Transformation is not a new term, but the emergence of a range of disruptive technologies, from AI to quantum computing, has made it more urgent than ever for businesses to find a clear guiding path towards proven approaches to this challenge,' said Steve Nunn, President and CEO of The Open Group. 'Our track record of bringing industry stakeholders together in a neutral, collaborative space means that The Open Group is well placed to add value to one of the world's major areas of investment.' To learn more about The Open Group Open Digital Transformation Forum, please visit here. About The Open Group The Open Group is a global consortium that enables the achievement of business objectives through technology standards and open source initiatives by fostering a culture of collaboration, inclusivity, and mutual respect among our diverse group of 900+ memberships. Our Membership includes customers, systems and solutions suppliers, tool vendors, integrators, academics, and consultants across multiple industries.
